PR95421

LAUSANNE, Switzerland, April 11, 2022 /PRNewswire=KYODO JBN/ --

Pre-clinical & clinical exploratory poster presentations to highlight oncology

results with Debio 0123, xevinapant, and Multilink[TM] technology for antibody

drug conjugates

Debiopharm, (www.debiopharm.com/debiopharm-international/) an oncology and

infectious disease focused biopharmaceutical company based in Switzerland,

today announced data releases on 3 investigational products including Debio

0123 (Selective WEE1 inhibitor), clinical exploratory results for xevinapant

(IAP inhibitor), and 2 Multilink[TM] technology posters (antibody drug

conjugate linker) at the 2022 Annual American Association for Cancer Research

(AACR) meeting in New Orleans, Louisiana. The AACR conference serves as the

focal point of the cancer research community to gather together and share

advances in oncology science. Debiopharm and their partners' poster

presentations represent scientific progress in the research of these compounds

leveraging novel modes of action and new delivery methods in development to

treat cancer types with high unmet needs.

"Scientific cancer research is evolving quickly, bringing us the insights

needed to better develop safer and more effective anti-tumor therapies. Our

ultimate vision is to translate these findings into meaningful outcomes for

patients in future clinical settings," explained Carolina Haefliger, Head of

Translational Medicine at Debiopharm.  

AACR 2022 Poster Sessions

Compound             Title                                   Date and Time      

N°

Debio 0123           The WEE1 inhibitor Debio 0123           Tue, April 12th,  

#4894

                     enhances the efficacy of standard       9:00am-12:30pm

                     of care DNA Damaging agents in          Section 5

                     lung cancer models

Multilink™           A novel antibody drug conjugate         Mon, April 11th,  

#4882

technology           linker enabling production of ADCs      1:30-5:00pm

                     with high drug to antibody ratios and   Section 21

                     fast payload release for improved

                     efficacy

Multilink™           The antibody-drug conjugate GENA-111    Mon, April 11th,  

#1716

technology           conjugated to auristatin F shows        1:30-5:00pm

(combined with       therapeutic potency in BCAM             Section 21

Genome & Co's        positive epithelial cancer

Antibody)

xevinapant           The IAP antagonist xevinapant in        Tue, April 12th,  

#603

(rights under Merck  combination with high-dose cisplatin    1:30-5:00pm

KGaA, Darmstadt,     chemoradiotherapy induces NF-kB and     Section 33

Germany)             apoptotic pathway biomarkers

                     in patients with high-risk, locally

                     advanced squamous cell carcinoma of

                     advanced the head and neck

About Debio 0123

Debio 0123[https://www.debiopharm.com/pipeline/debio-0123/] is an inhibitor of

WEE1 kinase, a key regulator of the G2/M and S phase checkpoints, activated in

response to DNA damage, allowing cells to repair their DNA before resuming

their cell cycle. WEE1 inhibition, particularly in combination with DNA

damaging agents, induces DNA breaks leading to the accumulation of DNA damage.

In conjunction with abrogation of other checkpoints such as those of the G1

phase of the cell cycle, the compound pushes the cells through cycle without

DNA repair, promoting mitotic catastrophe and inducing apoptosis of cancer

cells.

About Multilink[TM]

Multilink[TM][https://www.debiopharm.com/manufacturing-science/technology-pipeli

ne/multilink/] is a new cleavable linker platform suited for multidrug

attachment and compatible with any conjugation technology to produce ADCs with

high DAR (drug-to-antibody ratio), allowing the loading of multiple payloads on

an antibody for an enhanced therapeutic effect. This highly effective and

well-tolerated linker platform is available for use of other specialty biotech

or pharmaceutical companies to generate a proprietary, clinical-stage ADCs.  

About xevinapant

Xevinapant[https://www.debiopharm.com/pipeline/xevinapant/#head-and-neck-cancer]

, now exclusively licensed to Merck for product development and

commercialization, is a potential first-in-class potent, oral, small-molecule

inhibitor of IAPs (Inhibitor of Apoptosis Proteins). In preclinical studies,

xevinapant restored sensitivity to apoptosis in cancer cells, thereby depriving

them of one of their major resistance mechanisms to anticancer therapy.

Currently in phase III clinical research, in a randomized, placebo-controlled

phase II study, xevinapant has demonstrated preliminary evidence of efficacy in

combination with chemoradiotherapy (CRT) in patients with high-risk locally

advanced squamous cell carcinoma of the head and neck (LA SCCHN), with a

clinically significant and sustained clinical activity and an acceptable safety

profile compared with CRT alone.

About Genome & Co.

Since its establishment in 2015, Genome and Company develops next waves of

innovative drugs including anti-cancer microbiome therapeutics and novel target

immune checkpoint inhibitors. Through continuing open innovations with global

external collaborations and strategic investments, the company has expanded its

microbiome pipeline into brain diseases and continues to pioneer the market in

becoming a fully integrated global healthcare group capable of research,

development and manufacturing of first-in-class pharmaceutical modalities

including microbiome. For more information, please refer to

http://genomecom.co.kr/.

Debiopharm's commitment to patients

Debiopharm develops innovative therapies that target high unmet medical needs

in oncology and infectious diseases. Bridging the gap between disruptive

discovery products and international patient reach, we identify high-potential

compounds and technologies for in-licensing, clinically demonstrate their

safety and efficacy and then select large pharmaceutical commercialization

partners to maximize patient access globally.

Visit us www.debiopharm.com/

Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

- Picture is available at AP Images (http://www.apimages.com) -

Debiopharm Contact

Dawn Bonine – Head of Communications

dawn.bonine@debiopharm.com

Tel: +41 (0)21 321 01 11

Source: Debiopharm International SA